Home
    Disclaimer
    3-Me-PCPy molecular structure

    3-Me-PCPy Stats & Data

    M3ppy Tolicyclidine
    Psychoactive Class Dissociative / Stimulant
    Half-Life Unknown; community reports imply fast redistribution with subjective half-life ~1 h and elimination 2–4 h (unverified).

    Receptor Profile

    Receptor Actions

    Antagonists
    NMDA receptor antagonist (Ki ≈39 nM)
    Inhibitors
    Dopamine reuptake inhibitor (Ki 45 nM)
    Norepinephrine reuptake inhibitor (Ki 5.6 nM)
    Serotonin reuptake inhibitor (Ki 52.3 nM)
    Other
    Sigma-2 receptor ligand

    History & Culture

    3-Me-PCPy is a synthetic arylcyclohexylamine that has emerged as a novel psychoactive substance on the research chemical market. As a structural isomer of phencyclidine, it belongs to the broader family of dissociative compounds that have been systematically explored for their pharmacological properties. The substance has attracted attention from the research chemical community due to its unusual pharmacological profile, combining potent NMDA receptor antagonism with triple monoamine reuptake inhibition—a combination that produces both dissociative and stimulant effects. This dual activity profile distinguishes it from many other arylcyclohexylamines and has generated discussion among online harm reduction communities.

    Effect Profile

    Curated + 4 Reports
    Dissociative 4.3

    Strong dissociative depth, mania, and motor impairment

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    10
    Insight / Novel Thought×2
    0
    Motor / Sensory Impairment×1
    10
    Stimulant 3.6

    Moderate euphoria with low stimulation and anxiety/jitters

    Stimulation / Energy×3
    3
    Euphoria / Mood Lift×2
    6
    Focus / Productivity×2
    0
    Anxiety / Jitters×1
    2

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    15-45 minutes
    30 minutes - 1.0 hours
    1-2 hours
    1-2 hours
    1-6 hours
    Insufflated
    4-19 minutes
    19-45 minutes
    1-2 hours
    1-2 hours
    1-6 hours
    Rectal
    3-15 minutes
    19-40 minutes
    1-2 hours
    1-2 hours
    1-6 hours
    Smoked
    0-3 minutes
    4-15 minutes
    30 minutes - 1.5 hours
    1-2 hours
    1-6 hours

    Community Effects

    TripSit
    Positive
    stimulation dissociation sedation
    Negative
    psychosis

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown; community reports imply fast redistribution with subjective half-life ~1 h and elimination 2–4 h (unverified).
    Addiction Potential
    High—short duration, strong euphoria/drive, and perceived functionality promote compulsive redosing. Dissociative-class evidence notes habituation/compulsive patterns with ketamine/MXE; set firm limits and pre-portion doses.

    Tolerance Decay

    Full tolerance 1d Half tolerance 3d Baseline ~10d

    Anecdotal dissociative tolerance builds within 1–2 days of repeated exposure and decays over about 1–2 weeks; stimulant-like tolerance may build/resolve faster. Data derived from user reports of ACHs; no controlled studies.

    Cross-Tolerances

    3-MeO-PCP
    60% ●○○
    3-MeO-PCE
    60% ●○○
    ketamine-class dissociatives
    50% ●○○

    Experience Report Analysis

    Erowid
    4 Reports
    2021–2024 Date Range
    4 With Age Data
    6 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 4 experience reports (4 Erowid)

    4 Reports
    6 Effects Detected
    4 Positive
    1 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 4

    Euphoria 100.0% 70%
    Stimulation 100.0% 70%
    Focus Enhancement 75.0% 70%
    Tactile Enhancement 75.0% 70%

    Adverse Effects 1

    Confusion 75.0% 70%

    Real-World Dose Distribution

    62K Doses

    From 21 individual dose entries

    Insufflated (n=10)

    Median: 9.0mg 25th: 8.0mg 75th: 10.0mg 90th: 10.0mg

    Rectal (n=10)

    Median: 20.0mg 25th: 20.0mg 75th: 27.0mg 90th: 27.0mg

    Form / Preparation

    Most common forms and preparations reported

    Legal Status

    Country Status Notes
    Australia Controlled (analogue) Covered under analogue provisions as an arylcyclohexylamine derivative and structural isomer of phencyclidine. Treated as equivalent to the controlled parent compound under Australian drug law.
    Germany Controlled (NpSG) Covered under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as a generic arylcyclohexylamine derivative. The NpSG prohibits production and distribution but not personal possession.
    Japan Controlled (Designated Substance) Controlled under designated substance legislation as a generic arylcyclohexylamine derivative and structural isomer of phencyclidine. Manufacture, import, and sale are prohibited.
    United Kingdom Controlled (analogue) Covered under drug analogue laws as a generic arylcyclohexylamine derivative and structural isomer of phencyclidine. Likely controlled under the Psychoactive Substances Act 2016 which prohibits the production, supply, and importation of psychoactive substances.

    Harm Reduction

    drugs.wiki

    Insufflation: Multiple user reports describe intense, short-lived burn with prolonged rawness and next-day epistaxis; mitigate by finely crushing, using your own clean tool, alternating nostrils, and performing isotonic saline rinses pre/post. Acute effects: rapid rush (especially intranasal), sensory tunneling, limb numbness/ataxia, manic sociability; peaks within ~40–60 minutes and often fades by 2–3 hours. Redosing: short plateaus encourage frequent bumps—plan a hard cap on total session dose and time; waiting at least 90–120 minutes reduces stacking and helps gauge peak. Functionality trap: stimulation can feel higher and headspace shallower than 3-MeO-PCP, giving a deceptive sense of control; risky decisions (urban wandering, social disinhibition) and bingeing are common themes in reports. Urinary health: as with ketamine/MXE-class ACHs, frequent/heavy use is associated with LUTS and sometimes severe bladder injury; space sessions widely, hydrate moderately, and stop if any urinary pain, urgency, or hematuria appear. Combinations: avoid depressants (alcohol, GHB, opioids) due to aspiration/unconsciousness risk; avoid MAOIs and strong stimulants due to tachycardia/hypertension/mania potential; tramadol adds seizure and serotonergic risk. Mental health: dissociatives can precipitate paranoia/psychosis, especially with binges or sleep loss; avoid if you have a history of psychosis and ensure sleep after sessions. Driving: impairing even when you feel ‘functional’—do not drive or operate machinery until the next day and fully rested. Route-specific: rectal administration requires dilution and lubrication with gentle technique; avoid intravenous use (no documentation; unknown excipients). Equipment: use 0.001 g scales; never eyeball milligram quantities. Drug checking: mislabeling of ACHs is common—use reagent tests where available and prefer certified drug checking services to confirm identity/purity. Session hygiene: plan a sitter for higher doses; avoid eating heavy meals just before dosing to reduce nausea; have a calm, seated environment to reduce fall risk.

    References

    Data Sources

    ← Back to 3-Me-PCPy